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Summary
Background IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests 
as renal IgA deposition that leads to impairment and end-stage renal disease in 20–40% of patients within 10–20 years. 
In this trial (NEFIGAN) we aimed to assess safety and efficacy of a novel targeted-release formulation of budesonide 
(TRF-budesonide), designed to deliver the drug to the distal ileum in patients with IgA nephropathy.
Methods We did a randomised, double-blind, placebo-controlled phase 2b trial, comprised of 6-month run-in, 
9-month treatment, and 3-month follow-up phases at 62 nephrology clinics across ten European countries. We 
recruited patients aged at least 18 years with biopsy-confirmed primary IgA nephropathy and persistent proteinuria 
despite optimised renin-angiotensin system (RAS) blockade. We randomly allocated patients with a computer 
algorithm, with a fixed block size of three, in a 1:1:1 ratio to 16 mg/day TRF-budesonide, 8 mg/day TRF-budesonide, 
or placebo, stratified by baseline urine protein creatinine ratio (UPCR). Patients self-administered masked capsules, 
once daily, 1 h before breakfast during the treatment phase. All patients continued optimised RAS blockade treatment 
throughout the trial. Our primary outcome was mean change from baseline in UPCR for the 9-month treatment 
phase, which was assessed in the full analysis set, defined as all randomised patients who took at least one dose of 
trial medication and had at least one post-dose efficacy measurement. Safety was assessed in all patients who received 
the intervention. This trial is registered with ClinicalTrials.gov, number NCT01738035.
Findings Between Dec 11, 2012, and June 25, 2015, 150 randomised patients were treated (safety set) and 149 patients 
were eligible for the full analysis set. Overall, at 9 months TRF-budesonide (16 mg/day plus 8 mg/day) was associated 
with a 24·4% (SEM 7·7%) decrease from baseline in mean UPCR (change in UPCR vs placebo 0·74; 95% CI 
0·59–0·94; p=0·0066). At 9 months, mean UPCR had decreased by 27·3% in 48 patients who received 16 mg/day 
(0·71; 0·53–0·94; p=0·0092) and 21·5% in the 51 patients who received 8 mg/day (0·76; 0·58–1·01; p=0·0290); 
50 patients who received placebo had an increase in mean UPCR of 2·7%. The effect was sustained throughout 
followup. Incidence of adverse events was similar in all groups (43 [88%] of 49 in the TRF-budesonide 16 mg/day 
group, 48 [94%] of 51 in the TRF-budesonide 8 mg/day, and 42 [84%] of 50 controls). Two of 13 serious adverse events 
were possibly associated with TRF-budesonide—deep vein thrombosis (16 mg/day) and unexplained deterioration in 
renal function in follow-up (patients were tapered from 16 mg/day to 8 mg/day over 2 weeks and follow-up was 
assessed 4 weeks later).
Interpretation TRF-budesonide 16 mg/day, added to optimised RAS blockade, reduced proteinuria in patients with 
IgA nephropathy. This effect is indicative of a reduced risk of future progression to end-stage renal disease. 
TRF-budesonide could become the first specific treatment for IgA nephropathy targeting intestinal mucosal immunity 
upstream of disease manifestation.
Funding Pharmalink AB.
Introduction
Primary IgA nephropathy is the most prevalent chronic 
glomerular disease worldwide, with patients often 
diagnosed as young adults.1 About 20–40% of patients 
progress to end-stage renal disease within 10–20 years of 
diagnosis.2–4 Major risk factors for progression to end-stage 
renal disease are persistent proteinuria, hypertension, and 
reduced glomerular filtration rate (GFR).1,3,5,6 Kidney 
Disease: Improving Global Outcomes (KDIGO) guidelines 
for glomerulonephritis recommend renin-angiotensin 
system (RAS) blockade with angiotensin-converting-
enzyme inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs) as first-line treatment for patients with 
IgA nephropathy with proteinuria of more than 1 g/day 
(recommendation level 1B), and suggest up-titration as far 
as tolerated to the maximum recommended dose to 
achieve proteinuria of less than 1 g/day (recommendation 
level 2D).7 For patients with persistent proteinuria of more 
than 1 g/day and GFR greater than 50 mL/min per 1·73 m² 
despite 6 months’ optimised RAS blockade, KDIGO 
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suggest 6 months’ treatment with high-dose systemic 
corticosteroids (recommendation level 2C).7 However, use 
of high-dose systemic corticosteroids is associated with 
increased risks of adverse events and sequelae such as 
serious infections, hypertension, weight gain, diabetes, 
and osteoporosis.8–10 The benefit of systemic im-
munosuppression, in addition to dietary restrictions and 
use of multiple drugs to optimise the RAS blockade has 
recently been questioned in the STOP-IgAN trial.11 A 
targeted treatment with a favourable risk–benefit profile is 
needed for patients with IgA nephropathy who are at risk 
of progression to end-stage renal disease.
Evidence suggests a role for the mucosal immune 
system in the pathogenesis of IgA nephropathy.1,12,13 In 
patients with IgA nephropathy, mucosal B lymphocytes 
located in Peyer’s patches are thought to be primed to 
produce IgA1 that is galactose deficient (GdIgA1), which 
can form large immune complexes with anti-glycan IgG 
antibodies in the circulation.1,14–16 These complexes can 
bind to glomerular mesangial cells resulting in stimulation 
of cell proliferation, release of inflammatory mediators 
that promote proteinuria, and fibrotic remodelling, 
ultimately leading to loss of renal function.1,15 This 
pathogenesis suggests that local immunosuppression of 
mucosal B-lymphocyte activation and proliferation in 
Peyer’s patches could attenuate GdIgA1 production,17 
thereby reducing subsequent pathophysiological changes, 
assessed as a reduction in protein excretion by the kidneys.
A novel, oral, targeted-release formulation of the 
glucocorticosteroid budesonide (TRF-budesonide; 
Nefecon [Pharmalink AB, Stockholm, Sweden]) was 
developed to release the drug in the distal ileum, which 
has a high density of Peyer’s patches. The safety profile of 
TRF-budesonide was anticipated to be superior to high-
dose systemic corticosteroids because of its extensive first-
pass metabolism—less than 10% of budesonide enters 
systemic circulation.18 In a previous exploratory phase 2a 
trial,19 16 patients with IgA nephropathy received TRF-
budesonide (8 mg/day) for 6 months. The treatment 
resulted in a statistically significant reduction in 
proteinuria and was well-tolerated. In this phase 2b trial 
we aimed to evaluate the safety and efficacy of two different 
doses of TRF-budesonide in patients with IgA nephropathy 
who were at risk of progression to end-stage renal disease 




We did a randomised, double-blind, placebo-controlled 
phase 2b trial in patients with biopsy-confirmed primary 
IgA nephropathy and overt proteinuria considered at risk 
of progressing to end-stage renal disease. This trial was 
done at 62 nephrology clinics across ten European 
countries (Belgium, Czech Republic, Denmark, Finland, 
Germany, Italy, Spain, Sweden, the Netherlands, and 
the UK; appendix). The competent authorities and ethics 
committees for participating centres approved the trial, 
which was conducted from Dec 11, 2012, to June 25, 2015, 
in accordance with Good Clinical Practice and the 
Declaration of Helsinki, 2008.
Patients
We recruited men or women aged at least 18 years with 
biopsy-confirmed primary IgA nephropathy and overt 
proteinuria for the run-in phase. All patients provided 
written informed consent before enrolment. Inclusion 
criteria for randomisation to treatment included estimated 
GFR (eGFR) of at least 45 mL/min per 1·73 m² and a 
urine protein creatinine ratio (UPCR) of more than 
0·5 g/g or urinary total protein of at least 0·75 g/day—
levels that would be considered to increase the risk of 
Research in context
Evidence before this study
We searched PubMed up to April 26, 2016, with no start date 
restrictions, for published papers with no language restrictions 
about targeted-release formulation (TRF) of budesonide using the 
following search terms “targeted-release”, “budesonide”, 
“TRF-budesonide”, and “NEFECON”. We identified one relevant 
paper. In 2011, Smerud and colleagues reported an open-label, 
uncontrolled, exploratory phase 2a trial, in which 16 patients with 
IgA nephropathy received TRF-budesonide. Treatment for 
6 months resulted in a statistically significant reduction in 
proteinuria and was well tolerated.
Added value of this study
To our knowledge, this phase 2b trial is the only randomised, 
double-blind, placebo-controlled trial to investigate and show 
that TRF-budesonide, additional to optimised renin-angiotensin 
system blockade, reduced proteinuria and stabilised estimated 
glomerular filtration rate in patients with immunoglobulin A 
(IgA) nephropathy at risk of progression to end-stage renal 
disease. At 9 months, mean urine protein creatinine ratio had 
decreased by 24% in all TRF budesonide-treated patients 
combined versus an increase of 3% in placebo-treated patients. 
The effect was sustained throughout follow-up; mean urine 
protein to creatinine ratio (UPCR) decreased by 32% from 
baseline at 12 months for 16 mg/day versus <1% for placebo. 
Changes in 24-h protein excretion, urine albumin to creatinine 
ratio, and 24-h albumin excretion were consistent with the UPCR 
data. For 9 months, eGFR was stable with TRF-budesonide but 
decreased 10% with placebo. These effects are indicative of a 
reduced risk of future progression to end-stage renal disease.
Implications of all the available evidence
TRF-budesonide has the potential to become the first IgA 
nephropathy-specific treatment targeting intestinal mucosal 
immunity upstream of disease manifestation, reducing the risk of 
progression to end-stage renal disease.
See Online for appendix
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progression to end-stage renal disease.20 We used either 
24-h protein excretion or UPCR on the 24-h collection of 
urine to determine eligibility to overcome possible 
collection errors and deviations from normal creatinine 
excretion (eg, physically active and muscular men), thus 
minimising the risk of unintentionally excluding patients. 
Full eligibility criteria are in the appendix.
Procedures
Trial medication was an oral capsule formulation of TRF-
budesonide (Nefecon) or placebo, designed to provide 
sustained release of active compound that was delayed 
until the capsule reached the distal ileum,21 targeting the 
site with a high density of Peyer’s patches.
After screening, eligible patients were enrolled into a 
6-month run-in phase, a 9-month treatment phase, and a 
3-month follow-up phase; patient eligibility was assessed 
before run-in and treatment phases. During run-in, RAS 
blockade was optimised by up-titrating ACEIs and ARBs 
to a maximum recommended dose or maximum tolerated 
dose (in keeping with established clinical practice), to a 
target blood pressure of less than 130/80 mm Hg, UPCR 
of less than 0·5 g/g, and urine protein of less than 
0·75 g/day. At the end of run-in, patients with persistent 
proteinuria (UPCR ≥0·5 g/g or proteinuria ≥0·75 g/day) 
despite optimised RAS blockade, eGFR (estimated by the 
Chronic Kidney Disease Epidemiology Collaboration 
[CKD-EPI] serum creatinine equation,22 ≥45 mL/min) or 
measured GFR ≥45 mL/min per 1·73 m², and blood 
pressure 160/100 mm Hg or less were eligible for 
randomisation to treatment. Run-in phase directives are 
detailed in the appendix.
An independent Data and Safety Monitoring Board 
(DSMB) monitored all safety issues and reviewed data at 
the interim analysis.
Randomisation and masking
Patients were stratified according to their baseline UPCR 
(≤0·9 g/g and >0·9 g/g) at month 0 (baseline). We 
randomly allocated patients to treatment groups using a 
computer algorithm method of permuted blocks. Within 
each block, patients were allocated in a 1:1:1 ratio to 
16 mg/day TRF-budesonide, 8 mg/day TRF-budesonide, 
or placebo. All patients continued optimised RAS blockade 
treatment throughout the trial. Randomisation was done 
by Pharma Consulting Group AB (Uppsala, Sweden).
The trial was double-blind. Therefore, throughout the 
trial and the analyses, allocation to treatment groups was 
unknown to each patient, all trial staff (including the 
investigators and other staff who performed the 
randomisation and analyses), the sponsor, and the DSMB 
(the DSMB reviewed masked safety data and unmasked 
data were available should there be concerns).
To ensure masking, placebo capsules provided by 
the sponsor had the same appearance and route of 
administration as the active capsules. Patients self-
administered masked capsules, once daily, 1 h before 
breakfast during the treatment phase. During follow-up 
(months 9–12), patients who received 16 mg/day TRF-
budesonide during months 0–9 were tapered to 8 mg/day 
for 2 weeks while all other patients (ie, those who received 
TRF-budesonide 8 mg/day or placebo during months 0–9) 
received placebo to maintain masking. No further trial 
medication was administered after tapering.
Treatment code envelopes were provided for each 
randomised patient. In case of emergency, the code 
envelope could be opened. Any unmasked patient had to 
be withdrawn from the trial.
Outcomes
Our primary outcome was mean change from baseline in 
UPCR over the 9-month treatment phase. For primary 
analysis, we compared mean change from baseline in 
UPCR at 9 months between TRF-budesonide-treated 
patients (16 mg/day and 8 mg/day combined) and 
placebo-treated patients.
Secondary outcomes, assessed at various timepoints, 
were mean changes from baseline in UPCR at 12 months, 
eGFR, 24-h urine protein excretion, urine albumin 
creatinine ratio (UACR), and 24-h urine albumin 
excretion, which we calculated from measured 24-h urine 
samples. The tertiary outcome, the presence or absence 
of microhaematuria, was assessed by dipstick.
Patients attended screening visits to assess eligibility to 
enroll into the run-in phase. Patient’s attended between 
2–6 visits in the run-in phase and subsequent visits at 0, 1, 
3, 6, and 9 months in the randomisation and treatment 
phase and at 10·5 and 12 months in the follow-up phase. 
We used standardised questionnaires at each visit to ask 
patients about the presence of specific gastrointestinal-
related and corticosteroid-related adverse events. All 
solicited and spontaneously reported adverse events were 
recorded from screening until the end of trial, and coded 
using the Medical Dictionary for Regulatory Activities 
(version 16.0E). Vital signs, clinical chemistry, and 
haematology parameters were also assessed at each visit.
Statistical analysis
We used individual patient data from other relevant 
studies23,24 to estimate UPCR variability and the expected 
change from baseline at 9 months in those taking 
placebo. On the basis of these studies, the estimated 
geometric mean ratio of 9-month to baseline UPCR 
values was 0·88 (log SD 0·597). The corresponding 
geometric mean ratio for TRF-budesonide was 
estimated from a previous exploratory phase 2a trial19 as 
0·60 (log SD 0·488). Sample size calculations were 
based on the hypothesis that the true difference 
between TRF-budesonide (16 mg/day and 8 mg/day 
combined) and placebo in log UPCR change from 
baseline was log(0·60) – log(0·88) corresponding to an 
absolute difference of (1 – 0·6) – (1 – 0·88)=28%. Thus, a 
trial with 150 patients (50 per treatment arm) would 
provide more than 90% power to detect this level of 
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treatment effect for TRF-budesonide (16 mg/day and 
8 mg/day combined) versus placebo at the one-
sided 2·5% α level.
The primary outcome (mean change from baseline in 
UPCR over the 9-month treatment phase) was assessed 
on the full analysis set, defined as all randomised patients 
who took at least one dose of trial medication and had at 
least one post-dose efficacy measurement. A formal 
interim analysis of the primary outcome governed by the 
DSMB was prospectively planned and triggered when 
90 patients completed 9 months’ treatment, to ascertain 
whether the primary hypothesis could be rejected as well 
as to ensure patient safety and to exclude futility. No 
further statistical analyses were performed on the 
primary endpoint. All other statistical analyses were 
evaluated on final data. 
The interim analysis was not a simple analysis of the 
9-month datapoint in the first 90 patients. Rather, using 
mixed modelling methodology accepted by both the US 
Food and Drug Administration (FDA) and European 
Medicines Agency (EMA), the interim analysis included 
all patients who were randomised at the time the 
90th patient had completed 9 months’ treatment, even if 
some of these patients had data only up to the 1-month, 
3-month, or 6-month timepoint. The number of patients 
included in the interim analyses was therefore 149, of 
297 screened
207 enrolled into run-in
153 randomised
54 not randomised
37 did not meet randomisation criteria 
4 withdrew consent
3 had immunosuppressive or corticosteroid treatment
2 lost to follow-up or did not return to clinic 
2 (severe) adverse events 
1 pregnant or intended to become pregnant 
5 other
90 not enrolled
87 failed screening 
2 withdrew consent 
1 not in patient’s interest 
51 TRF-budesonide, 8 mg/day51 placebo
50 received intervention (safety set)
1 intervention not received (did not 
meet randomisation criteria)
50 full analysis set*
4 discontinued treatment or follow-up 
phase
2 adverse events 
1 initiated immunosuppressive or 
systemic corticosteroid treatment
1 did not tolerate ACEIs or ARBs
46 completed treatment and 
follow-up phases as planned
51 received intervention (safety set)
51 full analysis set*
11 discontinued treatment or follow-up 
phase
5 adverse events
1 initiated immunosuppressive or 
systemic corticosteroid treatment 
4 CTP violations 
1 pregnant or intended to become 
pregnant 
40 completed treatment and 
follow-up phases as planned
51 TRF-budesonide, 16 mg/day
2 intervention not received (did not 
meet randomisation criteria)
49 received intervention (safety set)
1 withdrawn (inability to swallow 
tablets)
48 full analysis set*
14 discontinued treatment or follow-up 
phase:
11 (severe) adverse events
1 withdrew consent 
1 personal reasons  
1 other (travelling distance)
34 completed treatment and 
follow-up phases as planned
Figure 1: Trial profile
ACEI=angiotensin-converting-enzyme inhibitors. ARBs=angiotensin receptor blockers. CTP=clinical trial protocol. *Full analysis set corresponds with the modified 
intention-to-treat analysis set.
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whom 90 had a 9-month measurement, with the 
remainder having some data at an earlier timepoint. We 
did mixed modelling analysis by assessing the patients’ 
proteinuria profile up to the 9-month timepoint. The 
treatment effect and p value at 9 months were extracted 
to provide the interim analysis result. This pre-planned 
approach offers more power than a simple analysis of the 
9-month datapoint in the first 90 patients. We set the 
threshold for significance for TRF-budesonide 
(16 mg/day and 8 mg/day) versus placebo on the primary 
outcome at 1·58% one-sided; futility could also be 
declared if predictive power was 5% or less. The α level 
applied at final analysis was 1·52% one-sided to ensure 
an overall type I error rate of 2·5% one-sided.
We prospectively planned that if statistical significance 
for the primary outcome was met during the interim 
analysis, the trial would continue, thereby allowing all 
patients to complete the trial and the analysis of 
additional endpoints on final data. All secondary and 
tertiary endpoints were thus analysed during the final 
analysis after all patients had completed the trial.  
We defined several post-hoc analyses after the interim 
analysis, and before the final database lock: treatment 
effects on UPCR and eGFR, CKD-EPI as a function of 
baseline UPCR, and eGFR.
All efficacy data were analysed using mixed-effect 
model repeated-measures analysis with fixed-effect terms 
for baseline log UPCR, randomised treatment group, 
Placebo 
(n=50)
TRF-budesonide 8 mg/day 
(n=51)




Age (years) 38·9 (12·0) 40·6 (13·0) 37·5 (11.9) 39·0 (12·3)
Sex
Male 35 (70%) 37 (73%) 33 (69%) 105 (71%)
Female 15 (30%) 14 (27%) 15 (31%) 44 (29%)
BMI (kg/m2) 27·5 (5·4) 26·5 (4·4) 27·8 (5·2) 27·3 (5·0)
Weight (kg) 85·2 (18·9) 80·9 (14·5) 86·7 (16·9) 84·2 (16·9)
Race
Asian 1 (2%) 0 (0%) 1 (2%) 2 (1%)
Causcasian 48 (96%) 49 (96%) 47 (98%) 144 (97%)
Other 1 (2%) 2 (4%) 0 (0%) 3 (2%)
Ethnicity
Hispanic/Latino 3 (6%) 11 (22%) 7 (15%) 21 (14%)
Non-Hispanic/non-Latino 47 (94%) 40 (78·4) 41 (85·4) 128 (85·9)
Blood pressure (mm Hg)
Systolic 128·1 (11·9) 127·7 (13·6) 126·7 (11·6) 127·5 (12·3)
Diastolic 80·2 (10·1) 80·3 (9·7) 78·1 (9·6) 79·6 (9·8)
UPCR (g/g) 0·8 (0·5–1·6) 0·8 (0·5–1·2) 0·8 (0·5–1·3) 0·8 (0·5–1·3)
24-h protein excretion (g) 1·2 (1·0–3·2) 1·1 (0·9–1·8) 1·3 (0·9–2·1) 1·2 (0·9–2·01)
UACR (g/g) 0·7 (0·4–1·3) 0·7 (0·5–1·0) 0·7 (0·4–1·2) 0·7 (0·4–1·1)
24-h albumin excretion (g) 1·1 (0·8–2·2) 1·0 (0·7–1·6) 1·1 (0·8–1·8) 1·0 (0·8–1·8)
eGFR CKD-EPI (creatinine formula; 
mL/min per 1·73 m²)
76·5 (23·2) 74·1 (25·8) 83·8 (25·9) 78·3 (25·1)
Patients with microhaematuria 40 (80%) 32 (63%) 42 (88%) 114 (77%)
Time from diagnosis to start of treatment 
(days)
1101 (294–2870) 1972 (623–4188) 1219 (498–2573) 1499 (496–3162)
Patients who made lifestyle changes 
during the run-in phase*
16 (32%) 18 (35%) 14 (29%) 48 (32%)
Patients previously treated with 
corticosteroids or immunosuppressants
7 (14%) 14 (28%) 6 (13%) 27 (18%)
Patients on ACEI alone, n (%, % on MRD) 21 (42%, 28%) 25 (49%, 22%) 26 (52%, 29%) 72 (48%, 26%)
Patients on ARB alone, n (%, % on MRD) 16 (32%, 20%) 14 (28%, 16%) 14 (29%, 19%) 44 (30%, 18%)
Patients on ACEI and ARB, 
n (%, % on MRD of one or both)
13 (26%, 20%) 12 (24%, 22%) 8 (17%, 13%) 33 (22%, 18%)
Patients on MRD of ACEI or ARB or both 34 (68%) 30 (59%) 29 (60%) 93 (62%)
Data are n (%), mean (SD), or median (IQR) unless otherwise stated. ACEI=angiotensin-converting-enzyme inhibitor. ARB=angiotensin receptor blocker. BMI=body-mass 
index. CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration Equation. eGFR=estimated glomerular filtration rate. MRD=maximum recommended dose. 
TRF-budesonide=targeted-release formulation-bedesonide. UACR=urine albumin creatinine ratio. UPCR=urine protein creatinine ratio. *Including salt intake, fluid intake, 
protein intake, fish oil intake, smoking, and exercise.
Table 1: Patient demographics and baseline characteristics (full analysis set)
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UPCR stratification level (UPCR ≤0·9 g/g and >0·9 g/g), 
visit, and visit by treatment group interaction. Patient and 
region were included as random effects. Region was 
defined on the country level, although Denmark was 
combined with Sweden and Belgium with the Netherlands 
due to small patient numbers per country. Restricted 
maximum likelihood estimation was used and inference 
on the fixed effects was based on robust (sandwich) 
variance estimation. Statistical analyses were performed 
using SAS version 9.3. This trial is registered with 
ClinicalTrials.gov, number NCT01738035.
Role of the funding source
The sponsor oversaw all study processes. AM is an 
employee of the sponsor, who contributed to the study 
design, provided study oversight, participated in data 
analysis, data interpretation, and writing of the report. 
Both placebo and TRF-budesonide treatments were 
provided by the sponsor. Following database lock and 
unblinding, the sponsor and all investigators had access 
to analyses performed on trial data. BCF had final 
responsibility for the decision to submit for publication.
Results
297 patients were screened between Dec 11, 2012, and 
Dec 26, 2013, and 207 patients were enrolled into the run-
in phase (figure 1). Following run-in, all patients eligible 
for randomisation to treatment received either a maximum 
tolerated dose or maximum recommended dose of ACEIs, 
or ARBs, or both. The last patient visit was on June 25, 
2015. 150 randomised patients received masked trial 
medication; 149 comprised the full analysis set (one patient 
was unable to swallow capsules; figure 1, appendix). Trial 
drug exposure is described in the appendix. Treatment 
groups (16 mg/day TRF-budesonide, 8 mg/day TRF-
budesonide, and placebo) were similar in demographic 
and baseline characteristics, with all patients using RAS 
blockade therapy (table 1). Patients maintained optimised 
RAS blockade treatment throughout the trial. In a few 
patients, changes in dose or drug were made in their RAS 
blockade (17 [11%] patients) or diuretics (ten [7%] patients). 
The frequencies of changes were comparable across the 
TRF-budesonide and placebo treatment groups (appendix).
In the pre-planned interim analysis (figure 2), the 
primary outcome of geometric least-squares mean UPCR 
at 9 months was reduced from baseline by 24·4% 
(–0·212 g/g) in all TRF-budesonide-treated patients 
combined versus an increase of 2·7% (0·024 g/g) in 
placebo-treated patients ([1–0·244]/[1+0·027]=0·74; 95% CI 
0·58–0·94; p=0·0066; figure 2). All point estimates and 
95% CIs are in the appendix. Hence, the primary objective 
of the trial was met at the interim analysis and the 
corresponding null hypotheses rejected. Geometric least-
squares mean changes from baseline were –27·3% for 
16 mg/day TRF-budesonide and –21·5% for 8 mg/day 
TRF-budesonide. The difference in UPCR at 9 months 
was significant for 16 mg/day TRF-budesonide versus 
placebo (0·71; 0·53–0·94; p=0·0092), but not for 8 mg/day 
TRF-budesonide versus placebo (0·76; 0·58–1·01; 
p=0·0290), which did not meet the adjusted p value at 
interim analysis (p≤0·0158).
Secondary and tertiary endpoints and post-hoc analyses 
were evaluated using the final analysis data. Change in 
UPCR from baseline at 9 months in the final analysis, 
when all patients had completed the trial (figure 2, 
appendix), was consistent with the change at 9 months in 
the interim analysis (figure 2, appendix).
Analysis of the reduction in UPCR at 9 months versus 
baseline showed that TRF-budesonide had a consistent 
effect on the relative change in UPCR regardless of 
baseline UPCR levels (appendix). Upon completion of the 
3-month follow-up, after cessation of trial medication, the 











































































Figure 2: Change in UPCR from baseline
Data are from all 149 patients in the full analysis set and are expressed as mean (bars show standard error of the 
mean). (A) Change in UPCR from baseline in patients after receiving placebo or TRF-budesonide (16 mg/day and 
8 mg/day combined, 16 mg/day, and 8 mg/day) for 9 months at the interim analysis (primary outcome). 
(B) Absolute mean change in UPCR from baseline in patients receiving 16 mg/day or 8 mg/day TRF-budesonide or 
placebo for the 9-month treatment phase and 3-month follow-up phase. UPCR=urine protein creatinine ratio.
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geometric least-squares mean reduction was sustained in 
the 8 mg/day TRF-budesonide group (–22·6% change 
from baseline) and decreased further in the 16 mg/day 
group (–32·0% change from baseline) versus an increase 
of 0·5% for placebo (figure 2 and appendix). Compared 
with placebo, the changes in UPCR at 12 months in both 
active treatment groups were statistically significant 
(16 mg/day vs placebo 0·68, 95% CI 0·57–0·96, p=0·0005; 
8 mg/day vs placebo 0·77, 0·62–0·96, p=0·0101; appendix).
Changes from baseline at 9 months and at 12 months 
in 24-h urine protein excretion, UACR, and 24-h urine 
albumin excretion (appendix) were consistent with the 
UPCR data (appendix). In the final analysis, changes in 
geometric least-squares-mean from baseline at 9 months 
in the 16 mg/day group versus placebo were UPCR 0·72 
(95% CI 0·56–0·92; p value not estimated); 24-h urine 
protein excretion 0·69 (0·53–0·91; p=0·0040); UACR 
0·68 (0·50–0·91; p=0·0053); 24-h urine albumin 
excretion 0·66 (0·48–0·89; p=0·0035; appendix).
eGFR remained stable in the TRF-budesonide groups 
but decreased in the placebo-treated group during the 
treatment phase in the final analysis, as shown by 
percentage changes at 9 months (figure 3) and by absolute 
mean changes in eGFR from baseline across the 
12 months (figure 3, appendix). Mean percentage change 
from baseline in eGFR at 9 months was –9·8% for 
placebo, 0·6% for 16 mg/day, and –0·9% for 8 mg/day 
(figure 3). Comparisons with placebo achieved statistical 
significance at 9 months (16 mg/day vs placebo 1·12%, 
95% CI 1·03–1·205, p=0·0026; 8 mg/day vs placebo 1·10%, 
1·02–1·18, p=0·0064). eGFR levels in the TRF-budesonide 
16 mg/day group were sustained throughout the trial 
(mean percentage change from baseline at 12 months, 
0·7% vs –10·9% for placebo; 1·11; 1·01–1·225; p=0·0134; 
appendix).
No participants died and none progressed to end-stage 
renal disease. 14 patients (three patients who received 
16 mg/day TRF-budesonide, four who received 8 mg/day 
TRF-budesonide, and seven who received placebo) 
reported treatment-emergent adverse events associated 
with worsening of renal function, or received high-dose 
systemic corticosteroid therapy, or both.
11 patients reported 13 treatment-emergent serious 
adverse events (appendix). Two were considered possibly 
associated with TRF-budesonide by investigators masked 
to trial medication: deep vein thrombosis (16 mg/day); 
and unexplained worsening of renal function, reported 
during follow-up after tapering from 16 mg/day to 
8 mg/day. Two serious adverse events in the placebo-
treated group were considered possibly associated with 
trial medication: both cases of increased proteinuria, one 
with a decline in renal function (details on adverse event 
reporting are in the appendix).
Total incidence of treatment-emergent adverse events 
was similar across treatment groups (table 2). The most 
frequently reported adverse event, nasopharyngitis, was 
reported by similar percentages of patients in each group. 
Bodyweight, blood pressure, and glycated haemoglobin 
(HbA1c) values did not significantly change from baseline 
in either TRF-budesonide group compared with placebo 
at the end of treatment (appendix, post-hoc analysis). 
Two patients receiving TRF-budesonide, both with a 
body-mass index of 36 kg/m² at baseline, had increases 
in HbA1c into the diabetic range (≥48 mmol/mol) at the 
end of treatment or during follow-up (appendix). We saw 
no other clinically relevant changes in clinical chemistry 
variables in any treatment group (the full list of clinical 
chemistry variables investigated is in the appendix). The 
incidence of gastrointestinal-related adverse events was 
similar in TRF-budesonide-treated and placebo-treated 
patients (appendix).





























































































Figure 3: Change in eGFR from baseline
Data are from all 149 patients in the full analysis set and are expressed as mean (bars show standard error of the 
mean). (A) Change in eGFR CKD-EPI from baseline in patients after receiving placebo or TRF-budesonide 
(16 mg/day and 8 mg/day combined, 16 mg/day, and 8 mg/day) for 9 months. (B) Absolute mean change in eGFR 
CKD-EPI from baseline in patients receiving TRF-budesonide 16 mg/day, 8 mg/day or placebo over the 9-month 
treatment phase and 3-month followup phase. CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration 
Equation. eGFR=estimated glomerular filtration rate.
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Solicited corticosteroid-related adverse events were 
more frequently reported by TRF-budesonide-treated 
patients (appendix). 18 patients experienced adverse 
events that led to discontinuation of treatment (11 in the 
16 mg/day group, five in the 8 mg/day group, two in the 
placebo group). Most patients who discontinued in the 
TRF-budesonide groups experienced corticosteroid-
related adverse events (appendix).
When assessed as a tertiary outcome in the final 
analysis, the proportion of patients with microhaematuria 
in the 16 mg/day TRF-budesonide group significantly 
decreased from 42 (88%) of 48 patients at baseline to 
21 (44%) of 48 at 9 months compared with 37 (74%) of 
50 placebo-treated patients at 9 months (odds ratio 0·22, 
95% CI 0·07–0·68; p=0·0041) but remained unchanged 
in the 8 mg/day-treated and placebo-treated groups.
Exploratory post-hoc analyses suggested that stabilisation 
of eGFR in TRF-budesonide-treated groups was 
independent of baseline UPCR and eGFR values, and that 
the degree of eGFR reduction in the placebo-treated group 
appeared related to the magnitude of baseline UPCR 
(appendix). To determine whether there was an influence of 
the extent of RAS blockade on eGFR, we compared eGFR 
changes in placebo-treated patients receiving maximum 
recommended dose versus the maximum tolerated dose of 
RAS blockade. This post-hoc analysis showed that the 
magnitude of decline in eGFR was comparable in placebo-
treated patients receiving RAS blockade therapy at the 
maximum recommended dose (–4·9 mL/min per 1·73 m² 
[SD 12·685]) versus at the maximum tolerated dose 
(–4·4 mL/min per 1·73 m² [9·187]).
Discussion
We report the results of the NEFIGAN trial in which 
9 months’ treatment with TRF-budesonide resulted in a 
significant reduction in UPCR versus placebo in patients 
with primary IgA nephropathy. This primary outcome was 
met in a prespecified interim analysis of data from the full 
analysis set population. The effect of TRF-budesonide was 
dose-dependent and time-dependent. Upon completion of 
the 3-month follow-up, after cessation of trial medication, 
the mean percentage reduction in UPCR was sustained in 
the 8 mg/day TRF-budesonide group and continued to 
decrease in the 16 mg/day group. The reductions in UPCR 
were consistent with changes in 24-h urine protein and 
albumin excretion and UACR, which were all sustained 
during the 3-month follow-up. This persistence of effect 
following cessation of treatment suggests a disease 
modifying effect.
Patients entering the treatment phase of this trial were 
at risk of progression to end-stage renal disease due to 
persistent proteinuria despite optimised RAS blockade. 
Placebo 
(n=50)
TRF-budesonide 8 mg/day 
(n=51)




Patients (%) Events Patients (%) Events Patients (%) Events Patients (%) Events
Any adverse event 42 (84%) 162 48 (94%) 270 43 (88%) 305 133 (89%) 737
Nasopharyngitis 10 (20%) 14 8 (16%) 16 10 (20%) 16 28 (19%) 46
Acne* 3 (6%) 3 8 (16%) 9 9 (18%) 10 20 (13%) 22
Joint swelling 2 (4%) 2 8 (16%) 8 9 (18%) 14 19 (13%) 24
Cushingoid* 3 (6%) 3 5 (10%) 5 8 (16%) 8 16 (11%) 16
Insomnia* 2 (4%) 2 6 (12%) 6 8 (16%) 9 16 (11%) 17
Diarrhoea 7 (14%) 9 1 (2%) 1 5 (10%) 5 13 (9%) 15
Dyspepsia† 4 (8%) 5 2 (4%) 2 7 (14%) 9 13 (9%) 16
Headache 3 (6%) 4 3 (6%) 3 6 (12%) 6 12 (8%) 13
Alopecia* 2 (4%) 2 4 (8%) 5 4 (8%) 4 10 (7%) 11
Back pain 1 (2%) 1 6 (12%) 8 3 (6%) 3 10 (7%) 12
Mood swings* 2 (4%) 2 3 (6%) 3 5 (10%) 5 10 (7%) 10
Oedema peripheral 2 (4%) 3 2 (4%) 3 6 (12%) 9 10 (7%) 15
Blood creatine 
phosphokinase increased
3 (6%) 3 3 (6%) 4 3 (6%) 3 9 (6%) 10
Hirsutism* 1 (2%) 1 3 (6%) 3 5 (10%) 5 9 (6%) 9
Hypertension 1 (2%) 1 3 (6%) 3 5 (10%) 5 9 (6%) 9
Muscle spasms 2 (4%) 3 5 (10%) 5 2 (4%) 2 9 (6%) 10
Abdominal pain† 1 (2%) 1 4 (8%) 4 3 (6%) 4 8 (5%) 9
Nausea 1 (2%) 1 4 (8%) 4 3 (6%) 5 8 (5%) 10
Upper respiratory tract 
infection
3 (6%) 3 2 (4%) 3 3 (6%) 3 8 (5%) 9
Adverse events reported by ≥5% of the total patient population. TRF-budesonide=targeted-release formulation-budesonide. *Corticosteroid-related adverse events solicited 
by questionnaire at every visit. †Gastrointestinal-related adverse events solicited by questionnaire at every visit.
Table 2: Treatment-emergent adverse events reported by ≥5% of all patients by preferred term (safety set)
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The further reduction in proteinuria was achieved by 
targeting an alternative pharmacological mechanism, 
using TRF-budesonide, irrespective of baseline UPCR, 
eGFR, and time since diagnosis of IgA nephropathy 
(appendix). Our findings support the generally accepted 
hypothesis that mucosal immune system dysfunction has 
a significant role in the pathogenesis of IgA nephropathy 
because TRF-budesonide targets the region of the 
gastrointestinal tract where Peyer’s patches reside at high 
density. Evidence and general acceptance is increasing 
that a reduction in proteinuria is associated with a 
reduced risk of end-stage renal disease in patients with 
IgA nephropathy, and time-averaged proteinuria is 
predictive of renal survival in these patients—the rate of 
decline of renal function and subsequent risk of renal 
failure are associated with higher levels of time-averaged 
proteinuria.5,20 A meta-analysis25 of trials for IgA 
nephropathy used contemporary statistical methodology 
to assess the possible surrogacy of the effect of treatment 
intervention (RAS blockade, fish oil, immunosuppression, 
and steroids) on proteinuria at 9 months to predict the 
effect of the intervention on clinical outcomes in end-
stage renal disease. The analysis suggested that an 
improvement in proteinuria at 9 months for a drug 
compared with control would be positively associated 
with an improvement in longer term end-stage renal 
disease outcome. For patients in the 16 mg/day TRF-
budesonide group, proteinuria in the form of UPCR and 
24-h urine protein excretion both decreased by about 30%, 
compared with the placebo-treated group. This level of 
proteinuria reduction is comparable with that conferred 
by RAS blockade in patients with IgA nephropathy,25 and 
in other chronic kidney diseases such as diabetic 
nephropathy.26 Proteinuria reduction was significantly 
associated with outcomes in end-stage renal disease in 
another meta-analysis26—for each 30% reduction in 
proteinuria by drugs that intervene in the RAS, the risk of 
end-stage renal disease (non-significantly) decreased by 
32% (95% CI –55 to 2).26 A treatment-induced decrease in 
proteinuria of 30% would result in a comparable 
reduction in the risk of end-stage renal disease.25
In our trial eGFR declined in the placebo-treated group 
but remained stable in the TRF-budesonide groups 
following 9 months’ treatment, an effect that persisted 
throughout follow-up in the 16 mg/day group. 
Stabilisation of eGFR in patients with IgA nephropathy 
is likely to predict a favourable outcome. All patients 
were on a maximum recommended dose or maximum 
tolerated dose of ACEI, or ARB, or both (as assessed by 
their investigator); thus, RAS blockade therapy remained 
optimised throughout the trial, with no dose changes 
during the treatment phase, except in a small number of 
individuals (percentage of maximum recommended 
dose of RAS blockade was increased for five of 
150 patients and decreased for six of 150 patients), dis-
tributed across the three treatment groups (appendix). 
Despite the maintenance of rigorous RAS blockade, the 
rapid rate of loss of eGFR observed in the placebo-treated 
group was greater than that seen in the STOP-IgAN 
study11 but consistent with other studies in patients with 
IgA nephropathy receiving optimised RAS blockade, 
albeit with generally higher levels of baseline 
proteinuria.24,27 A post-hoc analysis showed that the eGFR 
reduction in the placebo-treated group was related to 
baseline proteinuria, indicating that the response of this 
group of patients is consistent with the expectation that 
higher levels of proteinuria are associated with greater 
loss of eGFR (appendix). Because histological data are 
not available for the patients in all of these studies, 
speculation on the contribution of histopathological 
changes to the rate of eGFR decline is difficult. However, 
the deterioration in eGFR illustrates that this patient 
population is at risk of disease progression, current 
standard-of-care therapy is insufficient, and alternative 
interventions for patients with IgA nephropathy and 
persistent proteinuria are needed.
High-dose systemic corticosteroids and other potent 
immunosuppressive treatments have been studied in a 
number of randomised controlled trials with varying 
results.28 A consequence of these trials has been the 
necessity to test interventions in patients on optimised 
standard-of-care RAS blockade, as we did in this trial, 
and the investigators of the TESTING trial (a randomised 
controlled trial evaluating high-dose systemic 
corticosteroid therapy versus placebo [recruitment was 
stopped early and randomised treatment discontinued 
due to safety concerns, interim results published]),29 and 
the STOP-IgAN trial also did.11 The STOP-IgAN trial11 
assessed the potential benefit of systemic 
immunosuppression in addition to dietary restrictions 
and polypharmacy upon optimised RAS blockade, and 
was the first study in patients with IgA nephropathy to 
use such comprehensive supportive care. No difference 
in the rate of decrease in eGFR was observed between 
groups for the 3-year period of the trial.11 The slow annual 
loss of eGFR in the intensive supportive care group 
(1·6 mL/min per 1·73 m²) in the STOP-IgAN trial 
contrasts with the more rapid rate of loss of eGFR shown 
in other studies,24 including ours, in which a 6-month 
run-in phase was used to optimise RAS blockade. In our 
study, 62% of patients received the maximum 
recommended dose of ACE or ARB drugs (or both; 
table 1) and, on average, patients received 79% of the 
maximum recommended dose. In the placebo-treated 
group, 68% of patients received the maximum 
recommended dose of RAS blockade (table 1). By 
comparison, in the STOP-IgAN trial, 76% of patients in 
the supportive care group were on a maximum 
recommended dose of an ACEI or ARB. Whether this 
difference in RAS blockade is sufficient to account for 
the different rates of loss of renal function or whether 
other factors such as polypharmacy and the more 
rigorous application of dietary restrictions in the STOP-
IgAN trial (including limited salt intake) played a greater 
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part cannot be discerned from the available data. In our 
trial, a post-hoc analysis showed that eGFR was unlikely 
to be affected substantially by whether patients received 
the maximum recommended dose or maximum 
tolerated dose of RAS blockade therapy, because the 
magnitude of decline in eGFR was comparable in 
placebo-treated patients at the maximum recommended 
dose versus at the maximum tolerated dose.
16 mg/day TRF-budesonide resulted in a significant 
reduction in the presence of microhaematuria at 
9 months compared with placebo. Although the 
prognostic significance of haematuria disappearance in 
patients with IgA nephropathy has not been prospectively 
investigated, clinical and experimental studies suggest 
that haematuria is associated with glomerular and 
tubulointerstitial damage in IgA nephropathy and other 
glomerular diseases.30,31
In this trial, TRF-budesonide appeared to be safe 
and generally well-tolerated, although there was a 
dose-dependent trend in the incidence of solicited 
corticosteroid-related adverse events and in 
discontinuations due to these events (appendix). 
Budesonide, administered in a targeted-release oral 
dosage form, is subject to high first-pass metabolism, 
resulting in low systemic exposure (about 10% of 
administered dose).18 Some degree of systemic exposure 
was reflected in reduced cortisol excretion (data not 
shown) and the aforementioned dose-dependent trend in 
the incidence of solicited corticosteroid-related adverse 
events. However, several studies11,32 have reported higher 
incidences of diabetes mellitus or impaired glucose 
tolerance, hypertension, and weight gain in high-dose 
systemic corticosteroid-treated patients. Furthermore, 
increased incidences of serious and fatal infections were 
documented with high-dose systemic corticosteroid 
therapy in the STOP-IgAN trial11 (one of 55 patients) and 
TESTING trial29 (12 of 236 patients, including two deaths). 
By contrast, no serious infections were attributed to TRF-
budesonide in our trial and no statistically significant 
changes were observed for blood pressure, HbA1c, or 
bodyweight with TRF-budesonide versus placebo. 
Systolic and diastolic blood pressure levels were non-
significantly higher in the 16 mg/day TRF-budesonide 
group at the end of treatment compared with baseline 
values (appendix). Our trial data indicate that TRF-
budesonide might elicit fewer and less severe systemic 
effects and have a preferable tolerability profile than has 
previously been reported for high-dose systemic 
corticosteroid regimens, when used to treat patients with 
IgA nephropathy at risk of progression to end-stage renal 
disease, many of whom are young adults.11,32 However, 
this tolerability needs to be confirmed in larger studies 
than this phase 2b trial.
Proteinuria is a major risk factor for renal failure in 
IgA nephropathy.3,5 As addressed by Rauen and 
colleagues,11 clinically significant proteinuria has been 
arbitrarily defined as an excretion level greater than 
1 g/day (KDIGO guidelines).7 However, evidence from 
epidemiology studies20,33 indicates that patients with IgA 
nephropathy with proteinuria of 0·5 to 1 g/day are at 
increased risk of renal failure. Thus, to evaluate 
TRF-budesonide in a clinically relevant high-risk IgA 
nephropathy population, we selected a proteinuria 
threshold of either 0·75 g/day or 0·5 g/g UPCR (on a 
24-h collection). A threshold level of 0·75 g/day was 
similarly applied in the STOP-IgAN trial.
This trial is one of the largest randomised controlled 
trials in patients with IgA nephropathy in which RAS 
blockade was optimised before adjunct therapy. The 
primary objective of this trial was to assess the effect of 
TRF-budesonide on UPCR at 9 months, a proteinuria-
based measure and surrogate endpoint for renal failure. 
Although both a reduction in UPCR and stabilisation of 
eGFR were shown, the magnitude of relative risk 
reduction associated with TRF-budesonide treatment in 
patients with IgA nephropathy at risk of progression to 
end-stage renal disease needs to be quantified in a larger 
trial of longer duration. Another limitation of the present 
trial is that the patient population treated was almost 
exclusively white, thus the results also need to be 
confirmed in other populations. Additionally, allowing 
entry of patients into the study regardless of time since 
biopsy meant recent histopathology data were unavailable 
for all patients before randomisation. This absence 
prevented the implementation of a stratification strategy 
to discount imbalance of renal histology scores as a 
potential confounder. To our knowledge, no published 
pharmacokinetic data exist for TRF-budesonide in 
patients with IgA nephropathy. Patients with severe 
hepatic impairment were excluded from the study but 
whether patients with IgA nephropathy are subject to 
higher systemic exposure due to increased mucosal 
gastrointestinal absorption is unknown. Increased 
exposure of budesonide has been observed in chronic 
inflammatory bowel disease (11–21% vs 9–12% in healthy 
volunteers) but systemic exposure normalises after 
8 weeks of treatment.34
This trial showed that 9 months’ treatment with TRF-
budesonide resulted in reduced proteinuria and 
stabilised eGFR in patients with IgA nephropathy at risk 
of progression to end-stage renal disease. The observed 
effect was additive to optimised RAS blockade and 
supports the use of TRF-budesonide as adjunct therapy 
in patients with IgA nephropathy with persistent 
proteinuria. TRF-budesonide has the potential to become 
the first disease-specific treatment for IgA nephropathy, 
with a risk-benefit profile supportive of its use early in 
the course of disease.
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